Computationally designed broad coronavirus vaccine is safe and immunogenic in first human trial
Result confirmed
The takeaway
A Phase 1 trial in 39 volunteers found that a vaccine antigen designed entirely by computer (Cambridge / DIOSynVax, Jonathan Heeney) was safe and raised immune responses against SARS-CoV-2, SARS and bat coronaviruses.
Status
- Claim
Result confirmed
- Our reporting
- Medium confidence
- Verification
- Unverified claim
- Importance
- 3 of 5
- Last verified
- 29 September 2026
Your AI and this story
- GPT-6.2 Astra5 days after its cutoff
- Claude Opus 5.5In its training data
- Gemini 4 Hydrogen66 days after its cutoff
- Grok 4.75 days after its cutoff
It is after the cutoff of GPT-6.2 Astra, Gemini 4 Hydrogen and Grok 4.7, and can be in the training data of Claude Opus 5.5.
Key facts
- Phase 1, 39 volunteers; Journal of Infection (2026)
- Broad responses against SARS-CoV-2, SARS-CoV-1 and bat sarbecoviruses
- Design used computational structure-based antigen design and ML; exact AI contribution less specific than headlines suggest
What happened
An antigen engineered in silico to present conserved coronavirus epitopes completed a first-in-human trial.
Why it matters
It is an early human validation of computer-designed vaccine antigens, relevant to pandemic preparedness.
Sources
2 sources from 2 sites. Numbers match the chips in the text.
2 sources: 1 primary, 1 press
Primary
- DIOSynVaxdiosynvax.com, official
Press
- ScienceDaily: computer-designed coronavirus vaccine tested in peoplesciencedaily.com, press
Changes
- Filed